How long does it take to become resistant to Alpelisib-Piqray?

Alpelisib-Piqray is a targeted drug used to treat certain breast cancer patients whose tumors harbor PIK3CA mutations. Apelvis works by inhibiting the activity of PI3K protein kinase. However, resistance is a possibility, meaning patients may lose sensitivity to the drug. The time when drug resistance develops varies between individuals and there is no fixed time frame.

Some studies suggest that patients may develop resistance months or years after receiving treatment. The median treatment duration for patients who discontinued was 3.42 months, and the median treatment duration for patients who were still taking Apelvis was 3.95 months. Adverse events included hyperglycemia, rash, and diarrhea. Supportive care and interruption and/or dose reduction are necessary to control treatment-related side effects. Mechanisms of resistance may also vary among individuals, including further evolution of PIK3CA mutations or activation of other pathways. If a patient develops resistance to apelvis, doctors may consider other treatment options, such as combination therapy, switching to targeted drugs, or other treatment strategies. The specific treatment plan should be formulated by the doctor based on the patient's condition.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.